Alana Hippensteele is lead editor at Pharmacy Times®, Contemporary Clinic, and Pharmacy Times Oncology Edition®. She has a master's in Critical Theory and Creative Research from Pacific Northwest College of Art and a bachelor's degree in English and Art History. She has worked as an English instructor at Temple University and held editorial positions at American Cleaning & Hygiene and Tin House.
The FDA has granted enfortumab vedotin-ejfv both a regular approval and a new indication expansion for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received 1 or more prior lines of therapy.
Read More
Study: Ripretinib BID Well-Tolerated With Similar Safety Profile to Ripretinib QD in GIST
June 23rd 2021Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.
Read More
Pharmacy Fact: The ‘Healing Touch’ Approach to Medicine, Monarchical Legitimacy
June 4th 2021The medieval era was a horrible time to be alive, with all manner of unpleasant and disfiguring diseases raging the public with no known cures, leaving the hands of a king as their last hope for salvation.
Read More
The historical and cultural foundations of the use of psychedelic drugs, the failure of the war on drugs in the United States, and multiple examples of other countries successfully legalizing psychedelics without societal problems developing as a result make a clear argument for the legalization of psychedelic medicine.
Read More
Moderna Releases Positive Initial COVID-19 Vaccine Booster Data Against Variants of Concern
May 7th 2021Initial data from a phase 2 study showed that a single 50 µg dose of COVID-19 vaccines mRNA-1273 or mRNA-1273.351 given as a booster to individuals who were previously vaccinated increased their neutralizing antibody titer responses against SARS-CoV-2.
Read More